# Freenome Reports Improved Precancer Detection Data for Next-Gen Blood Test

- URL: https://stocks.freetheai.org/news/freenome-reports-improved-precancer-detection-data-for-next-gen-blood-test-3b42a4
- Published: 2026-10-11T17:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:FRNM](https://stocks.freetheai.org/symbols/NASDAQ-FRNM)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Freenome, Inc. (NASDAQ:FRNM) announced clinical validation results for an updated version of its SimpleScreen CRC blood screening test, showing higher accuracy in detecting advanced precancerous lesions. In a pivotal validation study, the updated test reached 18.2% sensitivity for advanced precancerous lesions, up from 13.7% in the previous trial. Detection for lesions with high-grade dysplasia rose to 41.9% from 30.5%, while overall colorectal cancer detection remained steady at 80.4% sensitivity with 90% specificity.

Finding precancerous lesions early is key to preventing colorectal cancer before it develops. The test performance improvements stem from updates to Freenome's assay and multiomics discovery algorithm. The first-generation SimpleScreen CRC received Food and Drug Administration approval in July 2026 and launched commercially in late September through partner Abbott Cancer Diagnostics. Higher sensitivity for precancerous indicators could help increase adoption among unscreened patients seeking non-invasive blood test alternatives.

Full detailed clinical findings will be presented at the American College of Gastroenterology Annual Meeting on October 14. Investors will watch how the performance refinements translate across the company's broader multi-cancer diagnostic pipeline and whether Abbott Cancer Diagnostics expands commercial distribution of the updated assay.

## Key points

- Freenome's updated SimpleScreen CRC blood test showed 18.2% sensitivity for advanced precancerous lesions, up from 13.7%.
- Sensitivity for lesions with high-grade dysplasia reached 41.9%, compared to 30.5% in prior testing.
- Overall detection sensitivity for colorectal cancer held firm at 80.4% with 90% specificity.
- The detailed validation results will be presented at the ACG 2026 Annual Meeting on October 14.

## Questions and answers

### What are the new clinical results for Freenome's CRC test?

Freenome's updated SimpleScreen CRC blood test demonstrated 18.2% sensitivity for advanced precancerous lesions and 41.9% sensitivity for high-grade dysplasia, while maintaining an 80.4% overall colorectal cancer detection rate and 90% specificity.

### When will Freenome present its full SimpleScreen CRC trial data?

Freenome will present detailed validation data for its updated colorectal cancer test on Wednesday, October 14, 2026, during a plenary session at the American College of Gastroenterology Annual Meeting in Nashville.

### Is Freenome's SimpleScreen CRC blood test FDA approved?

The Food and Drug Administration approved the first-generation version of SimpleScreen CRC in July 2026, and partner Abbott Cancer Diagnostics launched it commercially in late September 2026.